CN104519899A - 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法 - Google Patents

包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法 Download PDF

Info

Publication number
CN104519899A
CN104519899A CN201380024208.0A CN201380024208A CN104519899A CN 104519899 A CN104519899 A CN 104519899A CN 201380024208 A CN201380024208 A CN 201380024208A CN 104519899 A CN104519899 A CN 104519899A
Authority
CN
China
Prior art keywords
secad
cadherin
agent
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380024208.0A
Other languages
English (en)
Chinese (zh)
Inventor
萨比恩·布洛克松
斯特法诺斯·吉尔卡尼德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CN104519899A publication Critical patent/CN104519899A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201380024208.0A 2012-03-15 2013-03-15 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法 Pending CN104519899A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611390P 2012-03-15 2012-03-15
US61/611,390 2012-03-15
US201261736475P 2012-12-12 2012-12-12
US61/736,475 2012-12-12
PCT/US2013/032656 WO2013138790A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Publications (1)

Publication Number Publication Date
CN104519899A true CN104519899A (zh) 2015-04-15

Family

ID=49161879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380024208.0A Pending CN104519899A (zh) 2012-03-15 2013-03-15 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法

Country Status (8)

Country Link
US (2) US20150037354A1 (https=)
EP (1) EP2844270A4 (https=)
JP (1) JP2015514062A (https=)
KR (1) KR20140138956A (https=)
CN (1) CN104519899A (https=)
CA (1) CA2867456A1 (https=)
RU (1) RU2014141114A (https=)
WO (1) WO2013138790A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111208283A (zh) * 2018-11-21 2020-05-29 中国科学院上海生命科学研究院 增效的肿瘤抑制组合物及其应用
CN115040695A (zh) * 2021-03-09 2022-09-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043633A1 (en) * 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US10000479B2 (en) 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use
KR102486321B1 (ko) * 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842344A (zh) * 2004-06-25 2006-10-04 菲布雷克斯医疗研究及开发有限责任公司 衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455249B2 (en) * 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
EP2632489B1 (en) * 2010-10-27 2020-01-15 The Research Foundation for The State University of New York Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842344A (zh) * 2004-06-25 2006-10-04 菲布雷克斯医疗研究及开发有限责任公司 衍生自人血纤维蛋白原的Aα或Bβ链的肽用于治疗休克的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G DE SANTIS ET AL: "E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells", 《ONCOGENE》, vol. 28, no. 9, 19 January 2009 (2009-01-19) *
QUANRI JIN ET AL: "Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer", 《J MAMMARY GLAND BIOL NEOPLASIA》, vol. 13, no. 4, 25 November 2008 (2008-11-25), XP019645457, DOI: doi:10.1007/s10911-008-9107-3 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111208283A (zh) * 2018-11-21 2020-05-29 中国科学院上海生命科学研究院 增效的肿瘤抑制组合物及其应用
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
CN115040695A (zh) * 2021-03-09 2022-09-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用
CN115040695B (zh) * 2021-03-09 2023-10-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Also Published As

Publication number Publication date
CA2867456A1 (en) 2013-09-19
KR20140138956A (ko) 2014-12-04
US20150037354A1 (en) 2015-02-05
JP2015514062A (ja) 2015-05-18
EP2844270A4 (en) 2016-01-27
US20190008957A1 (en) 2019-01-10
EP2844270A1 (en) 2015-03-11
WO2013138790A1 (en) 2013-09-19
RU2014141114A (ru) 2016-05-10

Similar Documents

Publication Publication Date Title
US20210380671A1 (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
CN103275227B (zh) Axl抗体
US20190008957A1 (en) Combination therapies including inhibitors of the extracellular domain of e-cadherin
EP3202419A1 (en) Pvrig binding agents that modulate the hippo pathway and uses thereof
KR20180008449A (ko) 암에 대한 치료 및 진단 방법
KR20180119632A (ko) 암에 대한 치료 및 진단 방법
KR20180013881A (ko) 암에서의 pd-l1 프로모터 메틸화
JP2022512744A (ja) 肉腫様腎臓がんのための診断および治療方法
US8962808B2 (en) EGFR-related polypeptides and methods of use
KR20230025691A (ko) 삼중 음성 유방암을 치료하기 위한 방법과 조성물
AU2013231846A1 (en) Combination therapies including inhibitors of the extracellular domain of E-cadherin
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
HK40094175A (zh) 使用grem1拮抗剂治疗疾病的方法
HK1194681A (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150415

WD01 Invention patent application deemed withdrawn after publication